Cardiology

The Surpass Streamline stent is approved to treat unruptured large and giant wide-neck intracranial aneurysms.

Abbott’s updated MitraClip is a catheter-bases system that provides an alternative to open heart surgery for repairing mitral regurgitation.

A few months after performing a first-of-its-kind procedure in the US, members of the John Ochsner Heart and Vascular Institute surgical team explore what led to the surgical success.

The Cleveland Clinic’s pioneer of minority programs plans to end health disparity.

Pulmonary arterial hypertension is a rare, but deadly complication of systemic lupus erythematosus. French investigators sought to identify clinical features of patients with both. 

A study in the VA system found that only 19% of patients diagnosed with pulmonary hypertension received a PDE5 inhibitor prescription consistent with clinical guidelines.

The HVAD system is the only approved LVAD approved for implant via thoracotomy or median sternotomy.

AF is associated with major disease burden, predominately in the form of cardiovascular comorbidities. As a direct oral anti-coagulant, rivaroxaban has been a proven inhibitor of ischemic stroke risks in patients with AF.

The inverse association between coffee-drinking and all-cause mortality held even for participants with genetic variations affecting caffeine metabolism.

Trials of valbenazine for TD do not find that the treatment adds to cardiovascular disease risks associated with schizophrenia or the cardiovascular complications of antipsychotics.

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

The supplement included data from decade-long noninferiority PRECISION trial, which revealed safety data for using celecoxib in conjunction with aspirin.

Updated data on MoveDMD, a phase 2, open-label extension trial of edasalonexent in boys diagnosed with Duchenne muscular dystrophy (DMD), reports positive results.

How some of the most recent trial analysis narrows the clinical scope of GLP-1 and SGLT-2 targeting therapies.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.

Is there a relationship between polycystic ovary syndrome and diabetes? And if so, what are the variations in female patients?

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

New study finds that noninvasive assessment of CAD with CCTA may help reclassify risk and predict MACE in asymptomatic atherosclerosis.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?

The absolute risk reduction for patients with diabetes and recent ACS was 2.3% when on the PCSK9 inhibitor plus statin therapy.

Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.

The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.

hATTR compass program will empower people with accurate genetic information so they can make informed decisions about their healthcare.

The results suggest that this approach could streamline the diagnosis of diabetes, losing the need for the same elevated test needing to be repeated in a new blood sample.

Clinical data demonstrate that CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina.

Ray Comenzo, MD, highlights promising ANDROMEDA phase 3 trial, which evaluated the efficacy of subcutaneous daratumumab and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy for newly diagnosed light chain (AL) amyloidosis patients.